About ggngec

This author has not yet filled in any details.
So far ggngec has created 60 blog entries.

Stool transplantation for Clostridia difficile infection! Why in the world would you do that doctor?

Clostridia difficile infection (CDI) is epidemic in the United States with more than 300,000 new cases per year and 25,000 deaths per year. Although treatable with antibiotics, recurrent CDI is debilitating, costly and lethal. Recurrent CDI often does not resolve with antibiotic use, prompting unconventional measures such as stool transplantation or fecal microbiota transplantation [...]

By |2019-05-15T18:10:12+00:00August 17th, 2017|Media|Comments Off on Stool transplantation for Clostridia difficile infection! Why in the world would you do that doctor?

What is the best measure of quality in a gastroenterologist?

How do you choose a gastroenterologist for your screening colonoscopy?  Everyone wants “a good doctor” but how do you evaluate your gastroenterologist? If a gastroenterologist is diligent, thorough and spends adequate time during a colonoscopy, polyp detection improves.  Polyp detection is key since the removal of adenomatous (precancerous) polyps has been shown in tightly [...]

By |2019-05-15T18:16:02+00:00May 31st, 2017|Media|Comments Off on What is the best measure of quality in a gastroenterologist?

Proton Pump Inhibitors do not cause Alzheimer’s Disease.

Proton pump inhibitors (PPI) such as Prilosec, Nexium, Prevacid, Dexilant, and Aciphex have recently been associated with cognitive decline or dementia. In a study published this month in Gastroenterology, 10,486 volunteers within the NIH-supported Alzheimer’s Disease Centers who were aged 50 years and older and had either normal cognition or mild cognitive impairment at [...]

By |2019-05-15T18:16:15+00:00May 30th, 2017|Media|Comments Off on Proton Pump Inhibitors do not cause Alzheimer’s Disease.

Chronic Use Of Cannabinoid Derivatives May Lead To Increase In Cannabinoid Hyperemesis Syndrome.

In a retrospective study published in Clinical Gastroenterology and Hepatology researchers report “that in states that legalized marijuana for medical purposes, chronic use of cannabinoid derivatives has led to a significant increase in cannabinoid hyperemesis syndrome, characterized by episodes of severe nausea and cyclical vomiting.”

By |2019-05-15T18:16:24+00:00May 29th, 2017|Media|Comments Off on Chronic Use Of Cannabinoid Derivatives May Lead To Increase In Cannabinoid Hyperemesis Syndrome.

What Patients Need to Know About a New Study Linking PPIs to Dementia

A recently published study of claims data from a German health plan suggests an association between proton pump inhibitor (PPI) use and dementia in the elderly. Because the claims data used in the current study lack detailed sociodemographic data, such as diet, lifestyle and education, the researchers could not integrate these important factors into the [...]

By |2019-05-15T19:26:02+00:00May 15th, 2017|Media|Comments Off on What Patients Need to Know About a New Study Linking PPIs to Dementia

Gastroenterology Group of Naples Welcomes Dr. Sandra M. Jara

Gastroenterology Group of Naples Welcomes New Female Physician NAPLES, FL (Jan. 4, 2016) – Gastroenterology Group of Naples is pleased to announce the addition of Sandra M. Jara, M.D. Dr. Jara is board-certified in gastroenterology and will provide skilled endoscopy, colonoscopy, and small bowel capsule services. She will be accepting new patients starting January [...]

By |2019-05-15T19:25:18+00:00May 15th, 2017|Media|Comments Off on Gastroenterology Group of Naples Welcomes Dr. Sandra M. Jara

FDA Approves Lower-Priced Zepatier for Treatment of Hepatitis C

FDA Approves New Hepatitis C Drug January 29, 2016The Food and Drug Administration (FDA) has approved Merck & Co.’s Zepatier (elbasvir and grazoprevir), a once-daily, single-tablet combination therapy for hepatitis C. The drug is approved for patients with the most common type of hepatitis C in the US, genotype 1, as well as genotype 4. [...]

By |2019-05-15T19:24:34+00:00May 15th, 2017|Media|Comments Off on FDA Approves Lower-Priced Zepatier for Treatment of Hepatitis C